Search This Blog

Monday, April 14, 2025

Bessent Says Treasury Has Big Toolkit If Needed for Bonds

 


Treasury Secretary Scott Bessent played down the recent selloff in the bond market, rejecting speculation that foreign nations were dumping their holdings of US Treasuries, while flagging that his department has tools to address dislocation if needed.

“I don’t think there’s a dumping” by foreign investors, Bessent said in an interview Monday with Bloomberg Television while on a visit to Buenos Aires, Argentina. He pointed to what he said was increased foreign demand at auctions for 10-year and 30-year Treasury securities last week.

https://www.bloomberg.com/news/articles/2025-04-14/bessent-says-treasury-has-big-toolkit-if-needed-for-bond-market

No, A 50% Tariff Doesn't Mean A 50% Price-Hike

 by Randy White via AmericanThinker.com,

The tariff doomsday machine is roaring again.  This time, it’s over talk of a 50% tariff on certain imports.  

Predictably, the panic-peddlers are out in force, warning that such a tariff means retail prices will skyrocket 50%.  

It’s an easy line to chant, but it’s wrong — flat wrong — and anyone with a basic grasp of economics should know better.

Let’s make one thing clear: a tariff applies to the transaction value, not the final retail price.  The transaction value is what the importer pays the exporter, plus freight and insurance.  That cost is just the first step in a long supply chain.  By the time a product reaches the consumer, it’s been marked up to cover domestic shipping, warehousing, employee wages, utilities, sales tax, and profit margins for every hand it passes through.  The tariff is just one input among many.

Take a simple example.  

A retailer imports a widget with a $100 transaction value.  Add a 50% tariff, and the cost to the importer becomes $150.  That importer then sells it wholesale — perhaps at $200 — to a retailer, who marks it up again to $300 for sale.  That $50 tariff is now 16.7% of the retail price.  Even if every penny of the tariff is passed along, you’re not looking at a 50% increase in retail price — you’re looking at something closer to 17%.

But here’s the kicker: tariffs are not always fully passed on to the consumer.  Importers and retailers know they can’t raise prices beyond what the market will bear.  Sometimes they absorb part of the cost, cut expenses, renegotiate contracts, or shift to different suppliers.  The market reacts; it doesn’t just lie down and take it.

Still not convinced?  Look at the real-world data.  

The National Bureau of Economic Research analyzed the 2018–2019 U.S. tariffs on Chinese goods.  They found that for every 10% tariff, retail prices rose 1–2%.  So even a 50% tariff, if applied, might cause retail prices to edge up 5–10% — not 50%.  That’s a far cry from the alarmist headlines.

So why do politicians and media outlets keep pushing the scare narrative?  Easy: Fear sells.  

“Fifty percent” is a lot more dramatic than “maybe 5 to 10%.”  It’s easier to provoke outrage than to explain how pricing actually works.  They’re banking on the average person not understanding the difference between wholesale cost and retail price — or not caring enough to dig into the numbers.

Yes, tariffs matter.  They influence trade behavior.  They can increase some costs.  They can disrupt certain supply chains.  But they’re not some magic multiplier that doubles the price of your groceries or gadgets overnight.  

Anyone pushing that line is either economically illiterate or deliberately misleading you.

The next time you hear that a 50% tariff will mean a 50% price hike, don’t nod along.  Push back.  Ask for the math.  Demand the details.  

Because when it comes to tariffs and retail pricing, the facts just don’t support the hysteria.

https://www.zerohedge.com/political/no-50-tariff-doesnt-mean-50-price-hike

Trump Considers Deep Cuts to State Department

 The Trump administration might make major budget cuts to the State Department, including eliminating programs that promote democracy, support educational and cultural exchanges, fight drug trafficking, and assist U.N. peacekeeping efforts, according to a document obtained by Politico.

The proposed budget for fiscal 2026 includes just $28.4 billion for all activities carried out by the State Department, a decline of 48% from funding approved by Congress for 2025.

The document assumes the U.S. Agency for International Development has fully become part of the State Department. Cuts would include 54% in humanitarian assistance and 55% in global health funding.

Funding for the United Nations, NATO and 20 other organizations would end, according to the document. The administration is also considering closing up to three dozen U.S. diplomatic posts around the world.

It's unclear whether such cuts would gain approval in the Republican-controlled Congress.

The report comes the same day Pete Marocco, a State Department official who oversaw the dismantling of USAID, left the department after less than three months. According to The Wall Street Journal, Marocco sometimes disagreed with Secretary of State Marco Rubio’s scale and implementation of foreign aid cuts.

https://www.newsmax.com/newsfront/trump-state-department-budget-cuts/2025/04/14/id/1206862/

Bessent says White House will start interviewing candidates for next Fed chair this fall

  U.S. Treasury Secretary Scott Bessent on Monday said the White House expects to start interviewing candidates this fall to succeed Federal Reserve Chair Jerome Powell, whose term ends in May 2026.

Bessent told Bloomberg TV that would give the Trump administration about six months lead time before Powell leaves office.

https://www.investing.com/news/economy-news/bessent-says-white-house-will-start-interviewing-candidates-for-next-fed-chair-this-fall-3984558

Bristol Myers (BMY) Reports Unmet Goals in Key Trial for Camzyos

 Bristol Myers Squibb (BMY, Financial) has revealed disappointing outcomes from its Phase 3 ODYSSEY-HCM trial, which assessed the efficacy of Camzyos for adults with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). This trial aimed to evaluate improvements from baseline to Week 48 in specific health measures, including the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score and peak oxygen consumption, as compared to a placebo. Unfortunately, the trial did not achieve these dual primary endpoints.

Despite the setback, the company emphasized that no new safety concerns arose from this study. Roland Chen, MD, highlighted the trial’s contribution to understanding non-obstructive HCM, stressing the continued need for treatments in this area. He reaffirmed that these findings do not alter the positive benefit-risk profile of Camzyos as demonstrated in trials and real-world data for obstructive HCM.

This development marks the first Phase 3 clinical trial data for a cardiac myosin inhibitor in the context of non-obstructive HCM, providing valuable insights for future research and therapeutic strategies.

https://www.gurufocus.com/news/2778203/bristol-myers-bmy-reports-unmet-goals-in-key-trial-for-camzyos-bmy-stock-news

Harvard refuses Trump admin demands to curtail antisemitism on campus

 Harvard University said it will not comply with demands issued by the Trump administration aimed at curtailing antisemitism on campus, potentially putting billions in federal contracts and grants at risk.

“No government — regardless of which party is in power — should dictate what private universities can teach, whom they can admit and hire, and which areas of study and inquiry they can pursue,” the Ivy League school’s president, Alan Garber, wrote in a statemet Monday.

In March, the Trump administration warned it was looking at $256 million in federal contracts for the elite Cambridge, Mass.-based school, as well as $8.7 billion in additional “multiyear grant commitments,” claiming Harvard had failed to take meaningful action to root out antisemitism.

Demonstrators rally on Cambridge Common in a protest demanding Harvard leadership resist interference at the university by the federal government in on April 12, 2025.REUTERS
A Jewish student surrounded by pro-Palestinian protesters at a Harvard Business School “Stop the Genocide in Gaza” protest on Oct. 18, 2024.X/@AvivaKlompas
The Trump administration had threatened to withhold federal funding unless Harvard curbed antisemitism on campus.Getty Images
The Ivy League was ordered to implement multiple changes to maintain its “financial relationship with the federal government,” in a letter earlier this month from President Trump’s newly formed Task Force to Combat Anti-Semitism

Some of them included reforming its student discipline policies, dismantling all diversity, equity and inclusion (DEI) programs and stepping up its admissions screening of international students to “prevent admitting students hostile to the American values,” including “students supportive of terrorism or antisemitism.”

The prestigious university was also ordered to make admissions decisions based on merit alone and “cease all preferences based on race, color, national origin, or proxies thereof.”

Garber called the administration’s demands “unprecedented,” and said the laundry list of required reforms “makes clear that the intention is not to work with us to address antisemitism in a cooperative and constructive manner.”

He further claimed the task force’s missive “goes beyond the power of the federal government … violates Harvard’s First Amendment rights and exceeds the statutory limits of the government’s authority under Title VI.”

He added that it “threatens our values as a private institution devoted to the pursuit, production, and dissemination of knowledge.”

Columbia University was given a similar set of demands last month from Trump’s task force, to which it largely agreed to adhere to avoid losing around $400 million in federal grants.

https://nypost.com/2025/04/14/us-news/harvard-refuses-trump-admin-demands-to-curtail-antisemitism-on-campus-putting-billions-in-federal-aid-in-jeopardy/

Soleno Therapeutics Announces VYKAT(TM) XR Launch



Soleno Therapeutics (NASDAQ: SLNO) has officially launched VYKAT™ XR (diazoxide choline) extended-release tablets in the U.S. market, with first prescriptions already delivered to patients. The FDA-approved treatment, specifically designed for hyperphagia in Prader-Willi syndrome (PWS) patients aged four and older, received authorization on March 26, 2025.

VYKAT XR stands as the only FDA-approved treatment for hyperphagia, which is the primary cause of mortality in PWS patients. The company reports strong initial interest in the medication and has implemented Soleno ONE™, a comprehensive support program to facilitate access for patients, caregivers, and healthcare providers.